Enteral Feeding Formulas Market To Reach $10.5 Billion By 2030

The global Enteral Feeding Formulas Market size is expected to reach USD 10.5 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing incidences of targeted diseases and advancements in drug development are expected to drive the demand for disease-specific formulas. Clinical nutrition is increasingly used for the personalized treatment of diseases, such as cancer and cystic fibrosis. These conditions require special nutrition to avoid any kind of drug interaction.

For instance, in the case of cystic fibrosis, special digestive enzyme capsules are administered. The nature of these digestive enzymes can vary in individuals. Appropriate nutrition is critical for preterm infants, and early nutrition provision could influence better clinical outcomes & growth of the child, including neurodevelopment, decreased risk of Retinopathy of Prematurity (ROP), or prevention of Bronchopulmonary Dysplasia (BPD).

The commitment of NPOs and NGOs to preventing and caring for preterm birth, such as the ‘Every Woman Every Child’ movement of the UN, to advance the global strategy on women’s and children's health, is expected to boost the demand for neonatal & preterm enteral feeding formulas. Growing initiatives to spread awareness regarding the importance of nutrients among the patient population are expected to improve the current market scenario.

According to an article titled ASPEN Strives to Address Critical Gaps in Diagnoses, Care, and Treatment through Annual Malnutrition Awareness Week, published by ASPEN, around 10 hospitalized patients go undiagnosed every 60 seconds. Hence, this organization established Malnutrition Awareness Week in 2011 to spread awareness regarding malnutrition in hospitalized patients and educate healthcare professionals on the importance of nutrients among patients.

In case of medical necessity, Medicaid must cover enteral nutrition. However, there are no such regulations/mandates on private insurance companies. Moreover, as per the results of a survey conducted by NCBI, there is a huge lack of reimbursement for patients on Home Enteral Nutrition (HEN) and inadequate awareness among stakeholders regarding market opportunities, especially in lower-income countries.

List Of Key Players Enteral Feeding Formulas Market

• Abbott
• Danone S.A
• Fresenius Kabi AG
• Nestlé
• VICTUS
• Primus Pharmaceuticals, Inc.
• Meiji Holdings. Co., Ltd.
• Mead Johnson & Company, LLC

Request a free sample copy or view report summary: Enteral Feeding Formulas Market Report

Enteral Feeding Formulas Market Report Highlights

• Based on product, the standard formula segment led the market, accounting for 56.8 % of the market share in 2023. The availability of a wide variety of standard formulas, coupled with increased demand for low-cost nutrient formulations, are among the factors driving the market growth
• Based on flow type, the intermittent flow segment dominated the market with a share of 89.0% in 2023. This can be attributed to the fact that intermittent feeding has shown better tolerance in patients as compared to bolus feeding
• Based on stage, the adult segment, accounted for 90.4% of the overall market share in 2023, and is anticipated to be the fastest-growing segment over the forecast period
• The other indications segment accounted for the largest market share of 37.3% in 2023; the segment was followed by cancer. The dominant share can be attributed to the increasing incidences of malnutrition and other conditions associated with critically ill patients whose immune system is impaired
• Based on end-use, the home care segment is projected to showcase the fastest CAGR of 5.8% over the projection period.

Enteral Feeding Formulas Market Segmentation

Grand View Research has segmented the global enteral feeding formulas market based on Product, flow type, stage, indication, end-use, sales channel, region:

Enteral Feeding Formulas Product Outlook (Revenue, USD Million, 2018 - 2030)

• Standard Formula
• Disease-specific Formulas
• Alzheimer’s
• Nutrition Deficiency
• Cancer Care
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Malabsorption/GI Disorder/Diarrhea
• Others

Enteral Feeding Formulas Flow Type Outlook (Revenue, USD Million, 2018 - 2030)

• Intermittent Feeding Flow
• Continuous Feeding Flow

Enteral Feeding Formulas Stage Outlook (Revenue, USD Million, 2018 - 2030)

• Adults 
• Pediatrics

Enteral Feeding Formulas Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Alzheimer’s
• Nutrition Deficiency
• Cancer Care
• Diabetes
• Chronic Kidney Diseases
• Orphan Diseases
• Dysphagia
• Pain Management
• Malabsorption/GI Disorder/Diarrhea
• Others

Enteral Feeding Formulas End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Cardiology
• Neurology
• Critical Care (ICU)
• Oncology
• Others
• Home Care
• Long Term Care Facilities

Enteral Feeding Formulas Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Online Sales
• Retail Sales
• Institutional Sales

Enteral Feeding Formulas Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain `         
• Italy
• Russia
• Sweden
• Norway
• Denmark
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Singapore
• Latin America
• Brazil
• Mexico
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
• Kuwait